Zinc prices have surged over the past year due to supply shortages, mine disruptions, and strong demand from infrastructure and renewable energy projects. ASX investors can gain exposure through South32, Develop Global, and Sandfire Resources, each offering different risk and growth profiles.
NEXTDC (ASX: NXT) delivers strong revenue growth and record contracted utilisation, but heavy capex and negative statutory earnings cap near-term upside. AI-driven demand supports a justified premium, yet a sustained re-rating requires profitability acceleration and clearer cash-flow visibility.
CLINUVEL is a global photomedicine group commercialising SCENESSE for rare disorders while advancing vitiligo, ACTH and porphyria programs. Recent share strength reflects EMA vitiligo progress, stronger pipeline visibility and Nasdaq listing plans, though Phase III, regulatory and competition risks remain.
Avecho’s rally reflects Phase III CBD-insomnia progress, patent wins, and improving investor confidence. The biotech commercialises its TPM delivery platform across pharma, skincare, and animal health, while its production business supports higher-risk human health programs.
Artrya (ASX: AYA) is consolidating after a strong rally as investors assess its U.S. expansion, FDA progress, and commercial rollout of the AI-powered Salix platform. Despite the pullback, growing adoption and clinical milestones continue to support its long-term growth outlook.
Ansell (ASX: ANN) delivers double‑digit earnings growth, disciplined cost control, and strong cash conversion amid subdued market conditions, reinforcing margin resilience and balance‑sheet strength.
...
